Revenio Group Oyj

Helsinki Stock Exchange REG1V.HE

Revenio Group Oyj Price to Sales Ratio (P/S) on January 14, 2025: 6.59

Revenio Group Oyj Price to Sales Ratio (P/S) is 6.59 on January 14, 2025, a -4.05% change year over year. Price to sales ratio compares the stock price to the sales per share; higher suggests positive sentiment for future revenue growth.

Revenio Group Oyj 52-week high Price to Sales Ratio (P/S) is 9.86 on September 26, 2024, which is 49.56% above the current Price to Sales Ratio (P/S).
Revenio Group Oyj 52-week low Price to Sales Ratio (P/S) is 6.31 on April 25, 2024, which is -4.28% below the current Price to Sales Ratio (P/S).
Revenio Group Oyj average Price to Sales Ratio (P/S) for the last 52 weeks is 7.65.

Key data

Date	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield

Helsinki Stock Exchange: REG1V.HE

Revenio Group Oyj

CEO	Mr. Jouni Toijala B.Sc., M.B.A.
IPO Date	Oct. 2, 2001
Location	Finland
Headquarters	Äyritie 22
Employees	230
Sector	Consumer Discretionary
Industries Eyewear Medical Instruments Pharmaceuticals

Description

Revenio Group Oyj, a health technology company, designs, manufactures, and sells ophthalmic diagnostics and devices for the detection of glaucoma, macular degeneration, diabetic retinopathy, and cataracts in Finland, rest of Europe, and internationally. The company offers iCare IC100 and IC200 tonometers; iCare HOME, a device for self-measurement of eye pressure; imaging devices comprising iCare EIDON AF, a device with confocal retinal imaging; DRSplus, a device for detection of diabetic retinopathy; iCare MAIA, a microperimeter to measure the visual field; and iCare COMPASS, which provides fundus perimetry with true-color confocal retinal images. It also provides Oculo, an eye care software platform, which combines clinical communication, telehealth, remote patient monitoring and data analytics capabilities. Revenio Group Oyj was incorporated in 2001 and is based in Vantaa, Finland.

Key trends

Past 5 years